Webb1 dec. 2024 · Shanghai (ots/PRNewswire) - Jemincare, ein führendes pharmazeutisches Unternehmen aus China, gab heute bekannt, dass seine hundertprozentige Tochtergesellschaft, Shanghai Jemincare Pharmaceutical Co., Ltd. die exklusiven weltweiten Ex-China-Rechte für den Kras-Inhibitor JMKX1899, an HUYABIO International … Webb28 juni 2024 · Assignees: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD., JIANGXI JEMINCARE GROUP CO., LTD. Inventors: Shuchun Guo, Jiangwei Wang, Shan …
HUYABIO Announces the Exclusive License of the KRAS Inhibitor …
WebbShanghai Jemincare Pharmaceutical Co., Ltd was established in 2024 as the R&D center of Jiangxi Jemincare Group Co., Ltd. Shanghai Jemincare now has developed into a strong team with around 500 scientists comprised by 3 innovation centers, Small Molecule Innovative Center, Biologics Innovation Center and Technology Innovation Center. http://www.cnbg-virogin.com/ sharing maternal lines crossword
Jemincare Announces Exclusive License Agreement with
Webb2 Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China 3 University of Chinese Academy of Sciences, Beijing 100049, China 4 The Shanghai Advanced Electron Microscope Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China WebbFounded in 1999 in Nanchang, Jemincare now has more than 12,000 employees and its revenue has surpassed RMB 41 billion in 2024. As an international group, Jemincare … WebbFind company research, competitor information, contact details & financial data for Shanghai Jemincare Pharmaceutical Co., Ltd of Shanghai, Shanghai. Get the latest business insights from Dun & Bradstreet. sharing marketplace